Search
azficel-T (Laviv)
Indications:
- improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults. Conraindications:
- achondroplasia
- ataxia-telangiectasia
- Ehlers-Danlos syndrome
- epidermolysis bullosa
- hypertrophic scarring or keloid formation
- Marfan syndrome
- osteogenesis imperfecta
- skin cancer
- allergy to certain antibiotics (gentamicin, amphotericin), dimethyl sulfoxide (DMSO), or any bovine products
- skin infections of the face
- immunosuppression
- hemorrhagic diathesis
- Herpes labialis
- leukocytoclastic vasculitis [3]
Dosage:
- intradermal injection
Mechanism of action:
- autologous fibroblasts
General
organ transplantation
dermatologic agent
References
- LAVIV (azficel-T) Demonstrates Improvement in Acne Scarring
http://www.drugs.com/clinical_trials/laviv-azficel-t-demonstrates-improvement-acne-scarring-12597.html
- FDA: Vaccines, Blood & Biologics
Autologous Fibroblasts
http://www.fda.gov/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/ucm260485.htm
- Azficel-T (Intradermal Route)
Mayo Clinic
http://www.mayoclinic.com/health/drug-information/DR603475
- Smith SR et al.
A multicenter, double-blind, placebo-controlled trial of
autologous fibroblast therapy for the treatment of nasolabial
fold wrinkles.
Dermatol Surg 2012 Jul; 38:1234
PMID: 22409385